gene in individuals relapsing just after treatment method Together with the BCL2 antagonist venetoclax. sixty six Resistance to these brokers has long been related to these mutations in close to 70% of situations, Despite the fact that they usually are subclonal as well as their unique role causing resistance needs to be proven.Genetic susceptibili